Summarized by Masters of Longevity from PR Newswire.
Lilly reported Phase 3 and real-world results across tirzepatide, retatrutide and Foundayo.
Key Takeaways
- Retatrutide reduced sleep apnea events by up to 60.6%.
- Survey respondents found the oral GLP-1 pill simple and convenient.
- Zepbound and Foundayo are approved for long-term weight reduction.
